Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis

Phenylketonuria is a disease caused by congenital defects in phenylalanine metabolism that leads to irreversible nerve cell damage. However, its detection in the early days of life can reduce its severity. Thus, many countries have started disease screening programs for neonates. The present study a...

Full description

Bibliographic Details
Main Authors: Hamid Reza Shoraka, Ali Akbar Haghdoost, Mohammad Reza Baneshi, Zohre Bagherinezhad, Farzaneh Zolala
Format: Article
Language:English
Published: The Korean Pediatric Society 2020-02-01
Series:Clinical and Experimental Pediatrics
Subjects:
Online Access:http://www.e-cep.org/upload/pdf/kjp-2019-00465.pdf
id doaj-a6b66d6c2fc0418086b8c3692e2b361f
record_format Article
spelling doaj-a6b66d6c2fc0418086b8c3692e2b361f2020-11-25T03:53:08ZengThe Korean Pediatric SocietyClinical and Experimental Pediatrics2713-41482020-02-01632344310.3345/kjp.2019.0046520125553578Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysisHamid Reza Shoraka0Ali Akbar Haghdoost1Mohammad Reza Baneshi2Zohre Bagherinezhad3Farzaneh Zolala4 Health Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran Modeling in health research center, Institute for futures studies in health, Kerman University of medical sciences, Kerman, Iran Department of Medical Library and Information Science, Kerman University of Medical Sciences, Kerman, Iran Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, IranPhenylketonuria is a disease caused by congenital defects in phenylalanine metabolism that leads to irreversible nerve cell damage. However, its detection in the early days of life can reduce its severity. Thus, many countries have started disease screening programs for neonates. The present study aimed to determine the worldwide prevalence of classic phenylketonuria using the data of neonatal screening studies. The PubMed, Web of Sciences, Sciences Direct, ProQuest, and Scopus databases were searched for related articles. Article quality was evaluated using the Joanna Briggs Institute Critical Appraisal Evaluation Checklist. A random effect was used to calculate the pooled prevalence, and a phenylketonuria prevalence per 100,000 neonates was reported. A total of 53 studies with 119,152,905 participants conducted in 1964–2017 were included in this systematic review. The highest prevalence (38.13) was reported in Turkey, while the lowest (0.3) in Thailand. A total of 46 studies were entered into the meta-analysis for pooled prevalence estimation. The overall worldwide prevalence of the disease is 6.002 per 100,000 neonates (95% confidence interval, 5.07–6.93). The metaregression test showed high heterogeneity in the worldwide disease prevalence (I2=99%). Heterogeneity in the worldwide prevalence of phenylketonuria is high, possibly due to differences in factors affecting the disease, such as consanguineous marriages and genetic reserves in different countries, study performance, diagnostic tests, cutoff points, and sample size.http://www.e-cep.org/upload/pdf/kjp-2019-00465.pdfphenylketonuriaprevalenceneonatesscreeningmeta-analysis
collection DOAJ
language English
format Article
sources DOAJ
author Hamid Reza Shoraka
Ali Akbar Haghdoost
Mohammad Reza Baneshi
Zohre Bagherinezhad
Farzaneh Zolala
spellingShingle Hamid Reza Shoraka
Ali Akbar Haghdoost
Mohammad Reza Baneshi
Zohre Bagherinezhad
Farzaneh Zolala
Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis
Clinical and Experimental Pediatrics
phenylketonuria
prevalence
neonates
screening
meta-analysis
author_facet Hamid Reza Shoraka
Ali Akbar Haghdoost
Mohammad Reza Baneshi
Zohre Bagherinezhad
Farzaneh Zolala
author_sort Hamid Reza Shoraka
title Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis
title_short Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis
title_full Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis
title_fullStr Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis
title_full_unstemmed Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis
title_sort global prevalence of classic phenylketonuria based on neonatal screening program data: systematic review and meta-analysis
publisher The Korean Pediatric Society
series Clinical and Experimental Pediatrics
issn 2713-4148
publishDate 2020-02-01
description Phenylketonuria is a disease caused by congenital defects in phenylalanine metabolism that leads to irreversible nerve cell damage. However, its detection in the early days of life can reduce its severity. Thus, many countries have started disease screening programs for neonates. The present study aimed to determine the worldwide prevalence of classic phenylketonuria using the data of neonatal screening studies. The PubMed, Web of Sciences, Sciences Direct, ProQuest, and Scopus databases were searched for related articles. Article quality was evaluated using the Joanna Briggs Institute Critical Appraisal Evaluation Checklist. A random effect was used to calculate the pooled prevalence, and a phenylketonuria prevalence per 100,000 neonates was reported. A total of 53 studies with 119,152,905 participants conducted in 1964–2017 were included in this systematic review. The highest prevalence (38.13) was reported in Turkey, while the lowest (0.3) in Thailand. A total of 46 studies were entered into the meta-analysis for pooled prevalence estimation. The overall worldwide prevalence of the disease is 6.002 per 100,000 neonates (95% confidence interval, 5.07–6.93). The metaregression test showed high heterogeneity in the worldwide disease prevalence (I2=99%). Heterogeneity in the worldwide prevalence of phenylketonuria is high, possibly due to differences in factors affecting the disease, such as consanguineous marriages and genetic reserves in different countries, study performance, diagnostic tests, cutoff points, and sample size.
topic phenylketonuria
prevalence
neonates
screening
meta-analysis
url http://www.e-cep.org/upload/pdf/kjp-2019-00465.pdf
work_keys_str_mv AT hamidrezashoraka globalprevalenceofclassicphenylketonuriabasedonneonatalscreeningprogramdatasystematicreviewandmetaanalysis
AT aliakbarhaghdoost globalprevalenceofclassicphenylketonuriabasedonneonatalscreeningprogramdatasystematicreviewandmetaanalysis
AT mohammadrezabaneshi globalprevalenceofclassicphenylketonuriabasedonneonatalscreeningprogramdatasystematicreviewandmetaanalysis
AT zohrebagherinezhad globalprevalenceofclassicphenylketonuriabasedonneonatalscreeningprogramdatasystematicreviewandmetaanalysis
AT farzanehzolala globalprevalenceofclassicphenylketonuriabasedonneonatalscreeningprogramdatasystematicreviewandmetaanalysis
_version_ 1724479745221984256